

Consulting Management Committee  
Minutes: December 4, 2008

Attendees

Members: H. Frank, J. Hepworth (Chair), A.J. Pappanikou, R. Rubin, and T. Van Hoof.  
Staff: I. Krisst and S. Wetstone

The meeting was convened at 2:19 pm.

- 1) Minutes of the meeting of October 16 were approved unanimously.
- 2) UCHC request for action #7 – special rules for ad hoc purchasing committee  
  
R. Rubin has not yet received a written opinion from the Office of State Ethics.
- 3) Audit Report – The results of the recent audit with management's responses were discussed. The main changes were: a) the latest date a request form can be approved is the day before the start date of the activity, b) a sanctions policy must be developed for dealing with occurrences of non-compliance and sanctions must actually be issued, and c) additional data must be provided on the request form including total effort spend consulting and a self-report of all current research grants related to the contracting entity. The next audit will cover the period of time of 7/1/08 – 12/31/09 and one point of emphasis will be to ensure department heads have adequate information at their disposal to ensure consulting will not interfere with their faculty's ability to fully perform their assigned duties. The audit report and draft sanctions policy being considered by the Provost's Office will be distributed to the CMC by email.
- 4) SoM Policy and Guidelines on Interactions between the University of Connecticut School of Medicine and the Biomedical Industry. A SoM faculty forum was held to discuss this draft policy. The discussion was animated with widely different points of view expressed. Several units noted they had not been involved in the development of the draft policy and asked for an opportunity to now become involved. Dr. Koeppen announced that a new committee will be formed to further refine this policy and that committee would include these other units, including Dr. Wetstone to represent the CMC.
- 5) UCHC request for action #9 – promotional presentations. I. Krisst discussed the FDA rules with Dean McCarthy at the School of Pharmacy. The FDA rules pertain to a honest and complete disclosure of relevant data on single products and not comparisons with similar products or alternative forms of treatment.

The CMC discussed and reiterated the importance of the faculty member having a significant control over the content and educational materials used during presentations.

The committee adjourned at 3:24 pm.